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The astrocyte-specific enzyme glutamine synthetase (GS), which catalyzes the amidation
of glutamate to glutamine, plays an essential role in supporting neurotransmission
and in limiting NH4+ toxicity. Accordingly, deficits in GS activity contribute to epilepsy
and neurodegeneration. Despite its central role in brain physiology, the mechanisms
that regulate GS activity are poorly defined. Here, we demonstrate that GS is directly
phosphorylated on threonine residue 301 (T301) within the enzyme’s active site by
cAMP-dependent protein kinase (PKA). Phosphorylation of T301 leads to a dramatic
decrease in glutamine synthesis. Enhanced T301 phosphorylation was evident in a
mouse model of epilepsy, which may contribute to the decreased GS activity seen during
this trauma. Thus, our results highlight a novel molecular mechanism that determines GS
activity under both normal and pathological conditions.
Keywords: glutamine synthetase, phosphorylation, epilepsy, astrocyte, cAMP-dependent protein kinase
INTRODUCTION
The glutamate/GABA-glutamine cycle plays a fundamental role in the central nervous system
(CNS) by detoxifying the brain of excess neurotransmitters and ammonia as well as supplying
neurons with glutamine, which is a precursor of both GABA and glutamate. Glutamine synthetase
(GS) catalyzes an essential step in this pathway, the ATP-dependent condensation of glutamate and
ammonia into glutamine (Schousboe et al., 2013).
GS is expressed in several organs; however, its expression in the CNS is mainly
restricted to astrocytes (Suárez et al., 2002). Previous studies have shown that GS is
essential to survival, both in rodents and in humans (Häberle et al., 2005; He et al., 2010).
Moreover, inhibition of GS activity in vivo induces seizures in animal models (Rowe and
Meister, 1970; Eid et al., 2008; Boissonnet et al., 2012). Consistent with its central role
in neurotransmitter recycling and neurotransmission, GS expression and/or activity are
dramatically decreased in several neurological disorders, including mesial temporal lobe epilepsy
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(MTLE; Eid et al., 2004; van der Hel et al., 2005). Moreover,
a recent study has demonstrated that conditional ablation of
GS expression selectively in the mouse cortex of mice induces
spontaneous seizures (Zhou et al., 2018).
MTLE is a recurrent, complex pathology characterized by
neuronal loss and astrogliosis in the hippocampus and is the
most common type of drug-resistant epilepsy (Asadi-Pooya et al.,
2017). Several studies have shown that the cycling of glutamate to
glutamine is slower and glutamate levels are increased in MTLE
patients (Petroff et al., 2002; Cavus et al., 2005, 2008). Consistent
with these findings, GS activity is significantly reduced in the
sclerotic hippocampus (Eid et al., 2004; van der Hel et al., 2005),
leading to the hypothesis that the loss of the enzyme’s function
might contribute to the pathological state of this disorder.
However, themolecularmechanisms regulating the activity of GS
within astrocytes remain to be explored.
Here, we report that cAMP-dependent protein kinase (PKA)
phosphorylates GS on both threonine 301 (T301) and serine
343 (S343). Additionally, we show that the main site of
phosphorylation, T301, plays a fundamental role in regulating
the enzyme’s activity and is significantly increased in a mouse
model of epilepsy. Taken together, these results suggest that
PKA-dependent phosphorylation of T301 regulates the activity
of GS. Moreover, enhanced phosphorylation of this residue may
contribute to the deficits in GS activity arising during epilepsy.
MATERIALS AND METHODS
Animals
Eight to 12-week-old C57BL/6male mice were used for phospho-
specific antibody characterization and kainate injections. All
mice were housed in a 12-h light/dark cycle. All mice were bred
in-house at the Tufts University School of Medicine and handled
according to protocols approved by the Institutional Animal Care
and Use Committee (IACUC).
Antibodies and Expression Constructs
The following antibodies were used for Western-blotting:
GS mouse antibodies (Millipore, cat number MAB302 and
Santa Cruz, cat number sc-398034), tubulin mouse antibody,
pT301 and pS343 antibodies (created by PhosphoSolutions).
GS rabbit antibody (Sigma, cat number G2781) was used
for immunoprecipitation. GS was cloned into prK5 from
mouse genome (ATTG) and a MYC tag was inserted
between amino acids 372–373. A mutagenesis kit was
used to substitute T301 and S343 into alanine (T>A:
5′AACGCCCGGCGTCTGGCTGGATTCCACGAAACC, S>A:
5′ GAAGACCGTCGGCCTGCTGCCAATTGTGACCCC).
Cell Culture and Transfection
COS-7 cells were maintained in Dulbecco’s modified Eagle’s
medium/F12 (1:1) nutrient mix with 10% fetal bovine serum
and 1% of PenStrep (Thermo Fisher, cat number 11330–057).
The cells were transfected by electroporation (3 µg of
DNA/condition) and used 24 h after transfection. Astrocytes
were prepared from forebrain of 1–4 day-old mouse pups
of either sex as previously described (Schildge et al., 2013).
Cells were grown in Advanced modified Eagle’s medium
supplemented with 10% FBS and 1% P/S (Thermo Fisher, cat
number 11995073). Confluent cultures were shaken to obtain
an enriched astrocytes culture. The cells were trypsinized once
a week and used 3 weeks after shaking.
Western-Blotting
Cells or brain tissues were sonicated in lysis buffer consisting
of Tris, pH 8 20 mM, NaCl 150 mM, Triton 1%, EDTA
5 mM, NaF 10 mM, Na3VO4 2 mM, and Na pyrophosphate
10 mM. In order to detect GS, pT301 and pS343 signal, 15,
30 and 45 µg were loaded respectively from cell in culture
lysates and 15, 45 and 60 µg were loaded respectively from
brain lysates. Proteins separated by SDS-PAGE (10% gel) were
then transferred to nitrocellulose membranes and blocked in
6% milk in PBST for 6 h. Membranes were further incubated
with the appropriate primary antibody (6% milk in PBST
overnight), and after extensive washes, they were probed with
HRP-conjugated secondary antibodies for 1 h. Western blots
were developed using an enhanced chemiluminescence system
as per the manufacturer’s instructions (Amresco). Membranes
were imaged (ChemiDoc MP, Bio-Rad, Hercules, CA, USA) and
analyzed using ImageJ (National Institutes of Health, Bethesda,
MD, USA). For quantification, the ratio between GS, pT301 and
pS343 and the reporter protein (tubulin) was first analyzed.
We then normalized this value to the total GS to compare the
variation of T301 and S343 phosphorylation change between
each condition. In order to purify the signal of pT301 antibody,
it was premixed with non-phospho peptide overnight before
each use.
Immunoprecipitation and in vitro PKA
Assay
Cells were lysed in lysis buffer consisting of 20 mM Tris, pH 8,
150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 10 mM NaF,
2 mM Na3VO4, and 10 mM Na pyrophosphate for 1 h at 4◦C on
a circular rotor. Lysates were precleared with rabbit IgG attached
to protein G beads for 4 h at 4◦C. Lysates were then incubated
overnight with 50 µL of protein G sepharose and 3 µg of GS
antibody. Precipitated immunocomplexes were twice washed in
lysis buffer. Half of the sample was then incubated in 50 µl of
40 mMTris-HCl, pH 7.5, 5 mMmagnesium acetate with 200µm
ATP, and 0.1 µg of the catalytic subunit of PKA for 30 min
at 30◦C, and the other half was incubated in the same reaction
buffer without ATP as negative control.
Cloning, Expression and Purification of
Mouse GS
The gene sequence encoding mouse GS (2–373, Uniprot
assession #P15105) was synthesized with an N-terminal 6×His-
AVI-TEV tag (MHHHHHHGLNDIFEAQKIEWHEENLYFQG)
and cloned into pET-24a(+) to yield pNG189 (Blue Sky
Bioservices, Worcester, MA, USA). GS mutants T301A and
S343A were synthesized and cloned similarly (numbering refers
to the native mouse sequence). All sequences were codon
optimized for expression in Escherichia coli. GS mutants T301E
and T301V were generated with the QuikChange II Site-Directed
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Mutagenesis Kit (Agilent, Santa Clara, CA, USA) using
pNG189 as a template according to the manufacturer’s protocol.
For expression of GS, pNG189 was transformed into BL21
(DE3) cells (New England Biolabs, Ipswich, MA, USA). Cultures
were grown in LB medium with 25 µg/mL kanamycin at
37◦C with shaking until they reached an OD of 0.6, at which
point they were induced by addition of isopropyl β-D-1-
thiogalactopyranoside to a final concentration of 500 µM. After
induction, cultures were incubated at 16◦C overnight with
shaking. Cells were harvested by centrifugation and stored at
−20◦C until further use. For protein purification, all steps
were performed at 4◦C. Two liters worth of cells were thawed
and resuspended in lysis buffer containing 50 mM sodium
phosphate pH 7.5, 500 mM NaCl, 10% glycerol, 500 µM TCEP,
10 mM imidazole, and 1× Halt Protease Inhibitor Cocktail,
EDTA-Free (Thermo Scientific, Waltham, MA, USA). Cells were
lysed by passage through a French press. Lysates were cleared
by high-speed centrifugation and loaded onto a HisTrap HP
column (GE Healthcare, Chicago, IL, USA) pre-equilibrated
with 50 mM sodium phosphate pH 7.5, 500 mM NaCl, 10%
glycerol, 500 µM TCEP, and 10 mM imidazole. The column
was washed with the same buffer before eluting with a gradient
of 1 M imidazole. Fractions containing GS were identified by
SDS-PAGE, pooled, and concentrated to ∼2 mL. Crude GS was
then loaded onto a HiLoad 16/600 Superdex 200 pg column
(GE Healthcare, Chicago, IL, USA) pre-equilibrated with 50 mM
sodium phosphate pH 7.5, 500 mM NaCl, 10% glycerol, and
500 µM TCEP. GS was eluted with the same buffer at a flow
rate of 1 mL/min. Fractions containing GS were identified by
SDS-PAGE, pooled, supplemented with 1 mM MgCl2 and ATP,
and concentrated. Protein concentration was determined by
the Bradford method (Bio-Rad; #500–006) using bovine serum
albumin as a standard (Thermo Scientific, Waltham, MA, USA;
#23209). GS was stored at −80◦C. GS mutants were expressed
and purified similarly.
Thermal Shift Assays
Twenty-five-microliter reactions containing 5 µM wild-type
(WT) or mutant GS, 5× SyproOrange (Life Technologies,
Carlsbad, CA, USA; #S6651) and varying concentrations of
MgCl2 and ATP in 20 mM HEPES pH 7.5, 300 mM NaCl, 10%
glycerol, and 500 µMTCEP were prepared in white 96-well PCR
plates (ThermoFisher, Waltham, MA, USA; #AB0700/W). Plates
were incubated in a Bio-Rad CFX96 thermocylcer at 25◦C for
2 min then heated to 95◦C at a rate of 0.2◦C/5 s. Plates were
read at every 0.2◦C interval. Melting temperatures (Tm) were
determined by the maximum point of the dF/dT curve of the
HEX channel.
In vitro Phosphorylation Assays
Fifty-microliter reactions containing 5 µM WT or mutant
GS and 2.5 µM Protein Kinase A (PKA; Sigma; #P2645) in
50 mM imidazole pH 7.5, 10 mM MgCl2, 100 µM EDTA,
2 mM DTT, and 1 mM ATP were prepared and incubated
overnight at room temperature with or without 5 µM PKI
6-22 (Calbiochem; #539684). Kinase reactions lacking PKI were
stopped by the addition of PKI. Intact mass spectrometry analysis
was performed on a TripleTOF 5,600+ (AB Sciex) equipped
with a Duo Spray Ion Source and a Shimadzu LC 20-AD HPLC
system (Shimadzu Scientific Instruments). Samples were diluted
to 1 µM in 0.1% formic acid and separated on a Poroshell
300SB-C8 75 × 2.1 mm, 5 µm column (Agilent) at 30◦C with
a gradient of acetonitrile (5%–95%) in 0.1% formic acid. The
mass spectrometer was operated in positive ion and intact protein
mode. LC-MS data were acquired in TOF MS mode for m/z+
between 600 and 2,000. Peak areas for protein species were
determined following spectrum deconvolution using PeakView
(version 2.2) software.
GS Activity Assays
GS activity was measured using the γ-glutamyl hydroxamate
assay (Pamiljans et al., 1962). For recombinant GS, reactions
were prepared in 384-well plates (Greiner; #781101) in a final
volume of 10 µL by mixing 5 µL of a concentrated substrate
mix containing 0–700 mM glutamate, 40 mM ATP, and 40 mM
hydroxylamine in assay buffer (40 mM imidazole pH 7.4,
20 mM MgCl2, 1 mM DTT, and 0.01% Triton X-100) with
5 µL of concentrated enzyme mix containing either 150 nM
WT GS, 700 nM GS T301A, 700 nM GS T301E, or 200 nM
GS T301V in assay buffer. Negative controls lacking glutamate
were prepared in parallel. Reactions were allowed to proceed
at room temperature for 1 h. Reactions were terminated by
the addition of 50 µL of a stop/developer solution containing
163 mM FeCl3, 98 mM trichloroacetic acid, and 202 mM
HCl. Stopped reactions were mixed thoroughly, and their
absorbances were read at 540 nm. Background absorbance from
negative controls lacking glutamate was subtracted from all
measurements. These data were compared to standard curves
containing genuine γ-glutamyl hydroxamate (Sigma; #G2253),
which were prepared in assay buffer and developed as above;
kinetic parameters were extracted from non-linear fits of
these data.
Assays in tissue lysates were performed as above with
slight modifications. Samples were lysed by sonication in assay
buffer supplemented with 1% Triton X-100, 150 mM NaCl,
25 mM β-glycerophosphate, 2.5 mM sodium orthovanadate,
and 1× Protease Inhibitor Cocktail (Sigma; #P1860) and
centrifuged to remove insoluble material. Several common
protease and phosphatase inhibitors, including sodium fluoride,
sodium pyrophosphate, phenylmethylsulfonyl fluoride, and 4-(2-
aminoethyl) benzenesulfonyl fluoride were found to inhibit GS
(not shown) and should be avoided. Reactions were prepared
in 200 µL PCR tubes in a final volume of 20 µL by
mixing 10 µL of cleared lysate and 10 µL of a concentrated
substrate mix containing 700 mM glutamate, 40 mM ATP, and
40 mM hydroxylamine in assay buffer. Negative controls lacking
glutamate were prepared in parallel. Reactions were allowed
to proceed at room temperature for 30, 40, 50, or 60 min to
ensure linearity. Reactions were terminated by adding 100 µL
of stop/developer solution, after which they were centrifuged
to remove insoluble material. One-hundred microliters of each
supernatant was transferred to the well of a 384-well plate, and
their absorbances were read at 540 nm. Background absorbance
from negative controls lacking glutamate was subtracted from
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all measurements. Activity in lysates was compared to standard
curves containing genuine γ-glutamyl hydroxamate as above and
normalized by protein concentration using the Bradfordmethod.
PKA Inhibition Assay
The effect of methionine sulfoximine (MSO; Sigma; #M5379) on
PKA (EMDMillipore; #539481) activity was measured using the
PKA Colorimetric Activity Kit (Invitrogen; #EIAPKA) according
to the manufacturer’s protocol.
Data Analysis
Data were analyzed using GraphPad PRISM, and statistical
significance was determined at p < 0.05 using one-way ANOVA
followed by Dunnett’s multiple comparison post hoc test or
Student’s t-test for two groups.
RESULTS
GS Is Phosphorylated by PKA in vitro
In mammals, GS is a homomeric decamer comprising two
stacked pentameric rings that catalyzes the ATP-dependent
condensation of ammonia and glutamate to glutamine
(Krajewski et al., 2008). Protein sequence comparison between
rodents and human shows a high percentage of similarity (98%,
Figure 1A). Interestingly, both species exhibit two consensus
sites for PKA-dependent phosphorylation near the active
site of the protein localized on threonine 301 and serine 343
(T301 and S343, Figure 1A). However, neither of these predicted
sites of phosphorylation are found in prokaryotic forms of
GS (Figure 1B), suggesting that phosphorylation may play a
species-specific role in controlling enzyme activity.
In order to assess the possible role that phosphorylation
plays in determining GS activity, we initially expressed WT and
mutant versions of mouse GS modified with an N-terminal
6× His-Avi-TEV tag in E. coli. WT GS and mutants in which
T301 and S343 were mutated to alanine (T301A and S343A)
were affinity purified and exposed to the catalytic subunit of
PKA in the presence or absence of a peptide inhibitor of
PKA (PKI). Intact mass spectrometry analyses revealed that
WT GS and GS S343A were substrates for PKA-dependent
phosphorylation (Figure 1C), as indicated by an increase in
mass consistent with the addition of a single phosphoryl group
in the absence of PKI. Mutating T301 to alanine completely
abolished GS phosphorylation, thus indicating that T301 is the
primary phosphorylation site of PKA-mediated phosphorylation
of GS in vitro.
PKA Phosphorylation Decreases GS
Activity
T301 is located within the ‘‘glutamate flap,’’ a flexible active
site loop that enhances the binding of both glutamate and
ammonia and is thought to shield the active site from
water, thereby preventing premature hydrolysis of reactive
intermediates (Figure 2A, Supplementary Figure S1; Liaw
and Eisenberg, 1994; Alibhai and Villafranca, 1994; Gill and
Eisenberg, 2001; Gill et al., 2002; Krajewski et al., 2008).
Previous mutational studies of GS from Bacillus subtilis have
demonstrated that mutations in the flap can dramatically affect
the enzymatic activity of GS (Fisher et al., 2002; Wray and
Fisher, 2010). In order to understand how phosphorylation
of T301 affects GS activity, we treated GS with PKA in
the presence or absence of PKI and measured the initial
velocities of γ-glutamyl hydroxamate formation at various
concentrations of glutamate (Pamiljans et al., 1962). We
found that unphosphorylated GS (+PKI) was highly active and
displayed a low affinity for glutamate (Km app = 21 ± 1 mM;
n = 3; Figure 2B), which is consistent with previous studies
on GS from other rodents (Richterich-Van Baerle et al., 1957;
Wu, 1963; Lund, 1970). Importantly, treatment of GS with PKA
in the absence of PKI decreased the specific activity of GS
by approximately 40% at the highest glutamate concentration
tested but did not significantly alter glutamate affinity. The
decrease in activity correlated with a 74 ± 7% (n = 3)
degree of phosphorylation of GS as measured by intact mass
spectrometry (Figure 1B).
PKA Mediates Its Effects on GS Activity via
T301
To determine if the effects of PKA on GS activity are
mediated via direct phosphorylation we used site-directed
mutagenesis. First, we mutated T301 to glutamate (T301E),
whose negative charge mimics that of a phosphoryl group. We
then tested the activity of GS T301E and found, as expected,
that it had very low activity (about 25% of that of WT
at maximum glutamate concentration; Figure 2B) and was
insensitive to PKA-treatment.
To further explore structure-function relationships at
position 301, we tested the activity of GS T301A, which we
expected to exhibit WT-like activity but lack the capacity for
regulation by phosphorylation. GS T301A was insensitive
to PKA-treatment; however, its activity was similar to GS
T301E (approximately 20% of that of WT, Figure 2B).
In light of the low activity observed for GS T301A, we
questioned whether WT-like activity would be maintained
by the introduction of a bulkier valine residue, which is found
at this position in several bacterial species (Krajewski et al.,
2008; Wray and Fisher, 2010). Therefore, we generated a
T301V mutant and tested its activity. GS T301V exhibited a
similar specific activity to WT GS but displayed a significantly
lower affinity for glutamate (Km app = 145 ± 12 mM,
Figure 2B). As expected, PKA-treatment did not affect
T301V activity.
In addition to alterations in glutamate-binding and activity,
mutations within the glutamate flap have been shown to reduce
the sensitivity of GS to the inhibitor MSO (Wray and Fisher,
2010). MSO binds to the glutamate binding site of GS in an
initially reversible manner but is rapidly phosphorylated by GS in
the presence of ATP; in WT GS, the glutamate flap forms strong
hydrogen bonds with MSO phosphate, resulting in non-covalent
but nearly irreversible inhibition (Eisenberg et al., 2000; Gill and
Eisenberg, 2001; Jeitner and Cooper, 2014). We found that the
IC50 of MSO forWTGS was 182± 14µM (Figure 2C). The IC50
of MSO for GS T301V was 40-fold higher (7.6 ± 0.5 mM) and
>100 mM for GS T301E and GS T301A.
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FIGURE 1 | Glutamine synthetase (GS) is phosphorylated by protein kinase A (PKA) in vitro. (A) Sequence alignment between mouse and human GS protein
sequences. The amino acids that bind ammonia, ATP and glutamate are respectively labeled in bold green, blue and black. The underlined amino acids highlight the
reported lethal mutations in human and the red amino acids indicate the two consensus sites for PKA-dependent phosphorylation. (B) The weblogo motif for an
alignment between bacteria (Escherichia coli), yeast (Saccharomyces cerevisiae), plant (Arabidopsis thaliana), worm (Caenorhabditis elegans), chicken (Gallus gallus),
dog (Canis lupus), mouse (Mus musculus) and human (http://weblogo.berkeley.edu/, ∗highlights the putative PKA-dependent phosphorylation sites). (C)
Representative spectra from intact mass spectrometry analysis of purified WT and mutant GS treated with PKA in the presence (control) or absence (+ PKA) of PKI.
A single phosphorylation event is indicated by an 80-Da increase in mass in “+ PKA” samples relative to controls.
In order to rule out the possibility that the observed
differences in GS activity resulted from changes in GS stability
or Mg- or ATP-binding, we performed thermal shift assays
on GS in the presence of varying concentrations of MgATP,
which has been shown to stabilize GS (Krajewski et al., 2008).
We found that the melting temperatures of all GS constructs
used in this study were similar (approximately 55◦C) and that
incubation with MgATP increased their melting temperatures
to similar extents, indicating that the respective mutations do
not impact on enzyme stability or ability to bind MgATP
(Figure 2D). Collectively, these results indicate that residue
T301 is essential for efficient catalysis and that alterations at
this site, either by phosphorylation or mutation, can be a strong
negative regulator of GS activity. Additionally, these findings are
consistent with the idea that T301 phosphorylation exerts its
effects on GS activity by perturbing the position or dynamics of
the glutamate flap.
Analyses of GS Phosphorylation in Cell
Lines and the Brain Using Mass
Spectrometry
In order to assess the significance of our measurements using
purified GS, we expressed GS in COS-7 cells (Huyghe et al.,
2014). GS was immunoprecipitated from transfected COS-7 cells
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FIGURE 2 | PKA phosphorylation decreases GS activity. (A) Overall structure of a mammalian GS decamer, with an expanded view of the active site of GS (inset)
showing the locations of the glutamate flap (T301–N308; orange), T301 (carbon in green; oxygen in red), methionine sulfoximine (MSO; cyan) in the glutamate binding
site, manganese ions (pink), and ADP (magenta). Based on PDB ID 2QC8. (B) Initial velocity vs. glutamate concentration of purified WT and mutant GS treated with
PKA in the presence or absence of PKI as measured by the γ-glutamyl hydroxamate assay. Graph shows the mean ± standard error of the mean (SEM; n = 3). (C)
Activity of purified WT and mutant GS pretreated with MSO for 1 h at the indicated concentrations (with 20 mM ATP in assay buffer) as measured by the γ-glutamyl
hydroxamate assay. Results are normalized to the maximum activity for each protein. Graph shows the mean ± SEM (n = 3–5). (D) Melting temperatures of purified
WT and mutant GS in the presence of various concentrations of MgATP as measured by differential scanning fluorimetry. Graph shows the mean ± SEM (n = 3).
and incubated with active PKA in the presence or absence
of ATP. The samples were then subjected to SDS-PAGE and
stained with Coomassie blue. The major band at 45 kDa was
then digested with trypsin and phosphorylation was examined
using liquid chromatography coupled with mass spectroscopy
(LC-MS/MS). Possible sites of phosphorylation were then ranked
according to their ambiguity score (Ascore; Beausoleil et al.,
2006). Both T301 and S343 exhibited Ascores >19 compared
to control (-ATP), suggesting both residues are substrates for
PKA-dependent phosphorylation (Figure 3A). Encouraged by
our experiments using ‘‘back-phosphorylation,’’ we assessed
phosphorylation of GS in the brain. To do so, GS was
immunoprecipitated from mice hippocampal lysates. Following
SDS-PAGE and Coomassie blue staining, the principal band
at 45 kDa was subjected to LC-MS/MS as detailed above.
Ascores >19 were seen for both T301 and S343 (Figures 3B,C).
Thus, our experiments in COS-7 cells and brain reveal that in
common with our experiments in vitro, T301 is phosphorylated
by PKA. In addition, these findings suggest that GS is
also phosphorylated on residue S343 in cell lines and in
the brain.
Characterization of Phospho-specific
Antibodies Against GS
The results obtained using in vitro measurements of GS
phosphorylation and our LC-MS/MS studies prompted us
to create phospho-specific antibodies against T301 and
S343 (pT301 and pS343, respectively). Accordingly,
rabbits were immunized with a highly purified (>95%)
synthetic peptide centered and chemically phosphorylated
on the residue corresponding to T301 (bold) in GS:
KGGLDNARRLTGFHETSNIND. Antibodies were raised
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FIGURE 3 | Analyses of GS phosphorylation in cell lines and the brain using mass spectrometry. (A) Lysates from COS-7 cells transiently transfected with WT GS
were used to immunoprecipitate GS followed by an in vitro PKA assay. The sample (A) is the negative control (no ATP) and (B) is the experimental condition in the
presence of purified PKA and 200 µM ATP (n = 1). The samples were analyzed by LC/MS/MS and the associated table shows the ambiguity score for each peptide
(Ascore) the ratio between the peak intensity between phospho and non-phospho peptide (PI). The potential phosphorylation sites are labeled in red. (B) Lysates
from WT mice brain (1) were used to immnoprecipitate GS (n = 1). The samples were analyzed by LC/MS/MS and the associated table shows the results.
(C) Representative LC/MS/MS spectra associated for two phosphopeptides identified from GS immunoprecipitated from brain samples.
against S343 by injecting mice with synthetic peptide centered
and chemically phosphorylated on the residue corresponding
to S343 (bold): KKGYFEDRRPSANCDPYAVTE. High titer
antisera were then subject to tandem affinity purification on the
phospho- and dephospho-antigens (Jovanovic et al., 2004; Saliba
et al., 2012).
To test the specificity of these antibodies we expressed
WT GS, T301A and S343A in COS-7 cells (Figures 4A,D
respectively). Our laboratory previously determined that COS-7
cells do not express GS endogenously; therefore, those cells
are a great system to study the specificity of GS phospho
antibodies (Huyghe et al., 2014). Extracts of cells expressing
the respective constructs were then immunoblotted with pT301,
pS343 and GS antibodies. The pT301 antibody recognized a
major band of 45 kDa in cells expressing WT GS, as well
as a lighter band at the same molecular weight with GS
T301A (Figure 4A, n = 4). We then performed a peptide
competition assay by pre-mixing the antibody with the phospho
or non-phospho peptide (Supplementary Figure S2). We
observed that the pT301 signal disappears when pre-mixed
with the phospho peptide but not with the non-phospho
peptide, demonstrating that the pT301 antibody specifically
recognizes the T301 phosphorylation site; however, the lighter
band observed with the T301A point mutant also suggests that
pT301 antibody recognizes a second epitope on the phospho
peptide. Therefore, we tested whether we could increase the
specificity of this antibody by adding an extra purification step
consisting of pre-mixing pT301 with the non-phospho peptide.
Detection of this band was prevented by incubation with the
de-phospho-antigen (Supplementary Figure S2); therefore, we
added this extra step of antibody purification for the rest
of the study.
The same method was used to assess the specificity of the
pS343 antibody. In contrast to T301, no basal phosphorylation
of S343 was seen in COS-7 cells. In order to determine whether
S343 phosphorylation could be detected by increasing PKA
activity, the cells were treated with forskolin for 15 min (FSK;
20 µM), which resulted in the detection of a 45-kDa band in cells
expressing WT GS but not GS S343A (Figure 4D). Significantly,
the detection of this band was blocked by absorption with the
phospho- but not the dephospho-antigen and by pretreatment
with λ-phosphatase (Supplementary Figure S2).
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FIGURE 4 | Characterization of phospho-specific antibodies against GS. (A) Characterization of pT301 antibody using lysates from COS-7 cells transiently
transfected with GS WT or T301A point mutant. Total lysates were immnunoblotted with tubulin, GS or pT301 antibodies. Lysate from non-transfected COS-7 cells
was used as an additional negative control (NT, n = 4). (B) Lysates from WT mice forebrain were used for peptide competition assays to test pT301 specificity in
brain. Total lysates were immunoblotted with tubulin and pT301 antibodies (n = 3). (C) Lysates from WT mice forebrains were used for lambda-phosphatase assays
and immunoblotted with tubulin and pT301 antibodies (n = 3). (D) Characterization of pS343 antibody using lysates from COS-7 cells transiently transfected with GS
WT or S343A point mutant and immunoblotted with tubulin, GS or pS343 antibodies. PKA activator forskolin (FSK, 20 µM for 15 min) was used to increase
S343 phosphorylation signal. Total lysate from non-transfected COS-7 cells was used as an additional negative control (NT, n = 3). (E) Lysates from WT mice
forebrain were used for peptide competition assays to test pS343 specificity in brain. Total lysates were immunoblotted with tubulin and pS343 antibodies (n = 3).
(F) Lysates from WT mice forebrains were used for lambda-phosphatase assays and immunoblotted with tubulin and pS343 antibodies (n = 3).
In agreement with our studies conducted in COS-7 cells
(Figures 4A,D, Supplementary Figure S2), pT301 and
pS343 antibodies recognized bands of 45 kDa in brain
extracts, the detection of which was prevented by peptide
competition (Figures 4B,E) and λ-phosphatase treatment
(Figures 4C,F). Collectively, these findings show that the
antibodies directed against pT301 and pS343 recognize
specifically the phosphorylated sites of GS. Moreover, these
results suggest that the enzyme is phosphorylated on residues
T301 and S343 in cell lines and the brain.
GS Is Preferentially Phosphorylated on
T301 in COS-7 Cells and Astrocytes
To further assess GS phosphorylation, we expressed GS in
COS-7 cells and compared the effects of FSK treatment on
the phosphorylation of both residues T301 and S343 over a
time course of 60 min. Consistent with our initial studies, only
T301 exhibited basal phosphorylation, and FSK significantly
increased phosphorylation of T301 and S343 over time.
Significantly, PKA-dependent phosphorylation of T301 occurs
faster (Figure 5A, 15 min = 1.77 ± 0.21, p = 0.011, n = 4)
than on S343 (Figure 5A, 30 min = 0.13 ± 0.009, p = 0.046,
n = 4). Next, we examined the levels of basal phosphorylation
for each site in cultured astrocytes.While robust phosphorylation
of T301 was seen in these primary cells, S343 phosphorylation
was not detected (Figure 5B, n = 3). Collectively, these
results in cultured cells suggest that GS is preferentially
phosphorylated on T301.
MSO Binding Decreases
T301 Phosphorylation
MSO is a well-characterized GS inhibitor that binds
irreversibly to the glutamate binding site within this enzyme
(Eisenberg et al., 2000; Cloix et al., 2010). Given the strategic
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FIGURE 5 | GS is preferentially phosphorylated on T301 in COS-7 cells and astrocytes. (A) Lysates from COS-7 cells transfected with GS WT and treated with
forskolin (FSK, 20 µM) for different time-point were analyzed by immunoblotting with tubulin, GS, pT301 and pS343 antibodies. Graphs show the mean ± SEM
(∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, ANOVA Dunnett’s multiple comparison, n = 4). (B) Basal phosphorylation of pT301 and pS343 in cultured astrocytes was
determined by running an increasing range of protein concentration followed by immunoblotting with tubulin, GS, pT301 and pS343 antibodies. Total forebrain lysate
was used as an additional control (n = 3).
localization of T301 within the active site, we further sought to
assess whether MSO affects the ability of PKA to phosphorylate
GS. To do so, COS-7 cells transfected with WT GS were exposed
to 1 mM MSO for 60 min followed by 20 µM FSK for 30 min.
Pre-treatment with MSO partially blocked the FSK-induced
potentiation of T301 phosphorylation compared to control
(Figure 6A, FSK = 3.41 ± 1.15, MSO+FSK = 2.19 ± 0.88,
n = 4). Likewise, we observed that MSO tended to partially
reduce FSK-induced potentiation of S343 phosphorylation;
however, a significant increase was still observed compared
to control condition (Figure 6A, FSK = 0.46 ± 0.11,
MSO+FSK = 0.35± 0.12, n = 4, p = 0.03).
To assess the significance of the results obtained in COS-7
cells for events in the brain, mice were injected with either
saline or a pro-convulsive dose of MSO (75 mg/kg, Bernard-
Helary et al., 2000; Cloix et al., 2010). All MSO-injected mice
started seizing between 4 and 6 h after injection. After 8 h, the
mice were sacrificed and total GS levels and phosphorylation of
T301 and S343 were analyzed from hippocampal lysates. MSO
treatment significantly decreased T301 phosphorylation relative
to vehicle-treated controls (Figure 6C, MSO = 0.70 ± 0.06,
p = 0.0185, n = 5). We did not observe any significant change
in S343 phosphorylation in MSO-injected mice compared to
controls (Figure 6C, MSO = 1.11 ± 0.07, n = 5). These results
suggest that MSO treatment specifically reduces phosphorylation
of residue T301 in the hippocampus of WT mice. However,
a previous study has shown that MSO binding impairs the
antibody-antigen recognition that might lead to misinterpreting
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FIGURE 6 | MSO binding decreases T301 phosphorylation. (A) COS-7 cells transiently transfected with GS WT were treated with either MSO (1 mM for 60 min) or
corresponding control followed by forskolin treatment (FSK, 20 µM for 30 min). Lysates were analyzed by immunoblotting with tubulin, GS, pT301 and
pS343 antibodies. Graphs show the mean ± SEM (∗p < 0.05, ∗∗p < 0.01, ns, not significant, ANOVA Dunnett’s multiple comparison test, n = 4). (B) Relative activity
of purified mouse PKA treated with either PKI (1 mM) or MSO as measured by an ELISA-based assay using an immobilized peptide substrate. Graph shows the
mean ± SEM (n = 3). (C) WT male mice (8–12 weeks) were injected intraperitoneally by saline or MSO (75 mg/kg). Dissections of the hippocampi were performed 8 h
after injection and the tissues lysates were analyzed by immunoblotting with tubulin, GS, pT301 and pS343 antibodies. Graphs show the mean ± SEM (∗p < 0.05,
ns, not significant, unpaired t-test, n = 5). (D) The schema represents the antigen region recognized by different GS antibodies. Hippocampal lysates used in (C)
were analyzed by Dot-blot for pT301 and two different GS antibodies (GS1 and GS2). Graphs show the mean ± SEM (∗∗p < 0 0.01, unpaired t-test, n = 5).
the reduction of the signal for a decrease in protein levels
(Bidmon et al., 2008). To circumvent this technical issue, the
hippocampal samples from the saline orMSO-injectedmice were
used to perform dot-blot analyses to compare their respective
immunoreactivity after an additional denaturation step (10 min
at boiling temperature). As an additional control, a GS antibody
targeting the region surrounding the T301 residue was also used
(GS2). We did not detect any change in GS signal using the
regular GS antibody (GS1) or GS2, however, a reduction in
the T301 signal was still evident (Figure 6D). Therefore, MSO
binding leads to a decrease of T301 phosphorylation in vivo.
Finally, to investigate any possible direct inhibitory effects of
MSO on PKA activity, we directly tested how MSO affected the
enzyme activity of PKA in vitro. Under these conditions, MSO
did not directly modify PKA activity (Figure 6B). Accordingly,
these results provide further evidence that T301 phosphorylation
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FIGURE 7 | T301 phosphorylation is increased and GS activity is decreased in chemico-induced Status Epilepticus (SE). (A) WT male mice (8–12 weeks) were
injected intraperitoneally by saline or kainate (KA, 20 mg/kg). Dissections of the hippocampi were performed 1 h after SE and the tissues lysates were analyzed by
immunoblotting with tubulin, GS, pT301 and pS343 antibodies. Graphs show the mean ± SEM (∗p < 0.01, ns: not significant, unpaired t-test, n = 6). (B) GS activity
in hippocampal lysates from kainate- (SE) or saline-injected (Cont) mice as measured by the γ-glutamyl hydroxamate assay. Graph shows the mean ± SEM
(∗p < 0.05, unpaired t-test with unequal variances, n = 6).
is intimately linked to the catalytic mechanism of GS in the
hippocampus of WT mice.
T301 Phosphorylation Is Increased and GS
Activity Is Decreased in Chemico-induced
Status Epilepticus
Epilepsy leads to deficits in GS activity (Eid et al., 2004;
van der Hel et al., 2005); however, the underlying molecular
mechanisms are ill-defined. Thus, we assessed if alterations in
GS phosphorylation may be of significance in a mouse model of
epilepsy. To do so, we injectedmice with the chemico-convulsant
kainic acid (KA; 20 mg/kg, Silayeva et al., 2015). Subsequent
to KA injection, the development of Status Epilepticus (SE)
was measured by the development of stage V seizures as
defined on the Racine Scale (Racine et al., 1972). Sixty minutes
after entrance into SE, mice were sacrificed and hippocampal
lysates were subjected to immunoblotting with GS, pT301 and
pS343 antibodies. This revealed that T301 phosphorylation was
significantly increased in SE relative to control (Figure 7A,
SE = 1.71 ± 0.12, n = 5, p = 0.0017). In contrast, pS343 signal
(SE = 1.41± 0.14, n = 5, p = 0.27) and total GS (SE = 1.11± 0.04,
n = 5, p = 0.85) were not affected in KA-treated mice. Finally,
we assessed if in addition to modifying GS phosphorylation, SE
impacts on its activity using the γ-glutamyl hydroxamate assay.
The results revealed that GS activity was reduced by about 25% in
KA-injected mice relative to saline-injected controls (Figure 7B,
control = 5.5 ± 0.17, SE = 3.4 ± 0.49, n = 6, p = 0.02).
Thus, increased phosphorylation of T301 may contribute to the
reduced activity of GS activity observed in epilepsy.
DISCUSSION
In the brain, GS expression is restricted to astrocytes where
it plays a critical role in regulating glutamate levels and
ammonia by catalyzing their conversation to glutamine. Thus,
GS is accepted to play a central role in regulating amino
acid-mediated neurotransmission. Studies in peripheral tissues
and the CNS suggest that GS activity is modulated by
posttranslational mechanisms that include acetylation, tyrosine
nitration, oxidation, and ubiquitination (Bidmon et al., 2008;
Castegna et al., 2011; Nguyen et al., 2016).
GS shows remarkable phylogenic conservation, but it
is notable that all mammalian isoforms contain consensus
sites for phosphorylation by some protein kinases, including
PKA, that are not found in prokaryotes. To assess the
importance of phosphorylation—the most common protein
covalent modification—in regulating GS activity, we expressed
and purified the murine enzyme from E. coli. In vitro, GS is
phosphorylated by PKA to a final stoichiometry of 70% solely on
T301. T301 is within the glutamate flap region of GS, which plays
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a critical role in substrate binding and is essential for efficient
catalysis (Alibhai and Villafranca, 1994; Liaw and Eisenberg,
1994; Gill and Eisenberg, 2001; Gill et al., 2002). Phosphorylation
of GS significantly reduced its ability to synthesize glutamine,
an effect that was critically dependent on T301, as demonstrated
by mutation.
Mutation of T301 to either a glutamate residue, which mimics
the negative charge of a phosphoryl group or a conservative
alanine residue dramatically decreases enzyme activity and
increases the apparent Km for glutamate. In prokaryotes, a
hydrophobic valine residue is found at this position, and
conversion of T301 to valine in murine GS results in a relatively
mild reduction in glutamate affinity. In addition to these effects
on the catalytic properties of GS, mutating T301 greatly reduced
the affinity of GS for its inhibitor MSO. Importantly, mutations
of T301 did not modify GS stability or its ability to bind ATP
and magnesium, providing further evidence that these mutations
selectively impact glutamate binding. Collectively these results
suggest a vital role for the phosphorylation of T301 inmodulating
the activity of GS, consistent with its role in substrate binding
(Krajewski et al., 2008; Wray and Fisher, 2010).
To better understand the significance of our in vitro
measurements, we examined the phosphorylation of GS when
expressed in COS-7 cells and the brain. Confirming our
experiments with purified PKA, LC-MS/MS revealed that
T301 was phosphorylated in both systems. In addition, a second
site of phosphorylation, S343, was detected. In contrast to
T301, S343 is buried near the monomer-monomer interface
(Supplementary Figure S1), and its role remains unknown.
In agreement with our LC-MS/MS measurements, several
high-throughput mass spectrometry studies have detected
both T301 and S343 phosphorylation in the murine brain
(Goswami et al., 2012; Trinidad et al., 2012). To further
study GS phosphorylation, we produced phospho-specific
antibodies against T301 and S343. These tools confirmed
that both residues were phosphorylated in COS-7 cells and
brain lysates. Significantly, in COS-7 cells, phosphorylation of
T301 was faster than S343 upon activation of PKA. In cultured
astrocytes, phosphorylation of S343 was not detected under
basal conditions, but robust phosphorylation of T301 was seen.
Collectively, these results suggest that T301 is preferentially
phosphorylated upon the activation of PKA. They further suggest
that S343 phosphorylationmay be regulated in a cell type- and/or
context-specific manner.
To further assess the relationship between phosphorylation
of T301 and GS structure, mice were injected with MSO, which
irreversibly binds to the enzyme’s active site. Eight hours after
MSO injection, decreased T301 phosphorylation was evident in
the brain, while S343 and total GS levels were unaffected. Thus,
these results suggest that phosphorylation of T301 is intimately
linked with the catalytic mechanism of GS in the brain. Finally,
we assessed the effects of SE on GS phosphorylation and activity.
Deficits in GS activity and increased T301 phosphorylation
were evident in mice exhibiting SE, while total GS levels
and S343 phosphorylation were unaltered. Therefore, enhanced
T301 phosphorylation may contribute to the deficits in GS
activity that have been reported in human patients and animal
models of epilepsy (Eid et al., 2004; van der Hel et al., 2005; Eid
et al., 2012).
Collectively, our studies have revealed that GS is subject to
PKA-mediated phosphorylation, which leads to its inhibition
after SE. Thus, preventing its phospho-dependent inactivation
may be a potent mechanism to upregulate GS activity, which
may be of therapeutic value in epilepsy. Consistent with this
notion, PKA activity has been shown to be elevated in animal
models of SE and in human epileptic foci (Rakhade et al.,
2005; Lee et al., 2007; Bracey et al., 2009). It is important
to note that T301 in addition to S343 may also be subject
to phosphorylation by other protein kinases such as protein
kinase C. Thus, the phosphorylation of GS may be subject
to modulation by multiple cell signaling pathways under
control conditions and during seizures. Finally, as decreased
GS activity has been implicated in schizophrenia (Steffek
et al., 2008) and Alzheimer’s disease (Smith et al., 1991),
alterations in its phosphorylation may also be relevant to
these pathologies.
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